Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effects of Herombopag Olamine in Healthy Subjects
NCT06062680Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of hetrombopag in chronic primary immune thrombocytopenia (ITP) and aplastic anemia (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration (Cmax), Area Under the Curve from time 0 to last measurable concentration (AUC0-t) and 1 more. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
chronic primary immune thrombocytopenia (ITP)aplastic anemia
Beyond the preview
Go deeper on NCT06062680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062680.